152 related articles for article (PubMed ID: 16719543)
21. Effect of gastric emptying and entero-hepatic circulation on bioequivalence assessment of ranitidine.
Chrenova J; Durisova M; Mircioiu C; Dedik L
Methods Find Exp Clin Pharmacol; 2010; 32(6):413-9. PubMed ID: 20852750
[TBL] [Abstract][Full Text] [Related]
22. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
Liang Y; Carriere KC
Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
[TBL] [Abstract][Full Text] [Related]
23. Optimal adaptive sequential designs for crossover bioequivalence studies.
Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
[TBL] [Abstract][Full Text] [Related]
24. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
25. Optimal and/or Efficient Two treatment Crossover Designs for Five Carryover Models.
Gondaliya J; Divecha J
Int J Biostat; 2018 Nov; 14(2):. PubMed ID: 30471221
[TBL] [Abstract][Full Text] [Related]
26. On hybrid parallel-crossover designs for assessing drug interchangeability of biosimilar products.
Chow SC; Song F; Cui C
J Biopharm Stat; 2017; 27(2):265-271. PubMed ID: 28026996
[TBL] [Abstract][Full Text] [Related]
27. Crossover design in pharmacy research.
Cody RL; Slack MK
Ann Pharmacother; 1992 Mar; 26(3):327-33. PubMed ID: 1532519
[TBL] [Abstract][Full Text] [Related]
28. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Aggregated N-of-1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies.
Blackston JW; Chapple AG; McGree JM; McDonald S; Nikles J
Healthcare (Basel); 2019 Nov; 7(4):. PubMed ID: 31698799
[No Abstract] [Full Text] [Related]
30. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
Chen YI; Huang CS
Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
[TBL] [Abstract][Full Text] [Related]
31. Comparative bioavailability of two tablet formulations of acyclovir in healthy volunteers.
Al-Yamani MJ; Al-Khamis KI; El-Sayed YM; Bawazir SA; Al-Rashood KA; Gouda MW
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):222-6. PubMed ID: 9587049
[TBL] [Abstract][Full Text] [Related]
32. Comparative bioavailability of two tablet formulations of ibuprofen.
el-Sayed YM; Gouda MW; al-Khamis KI; al-Meshal MA; al-Dhawailie AA; al-Rayes S; Bin-Salih SA; al-Rashood KA
Int J Clin Pharmacol Ther; 1995 May; 33(5):294-8. PubMed ID: 7655769
[TBL] [Abstract][Full Text] [Related]
33. Comparative bioavailability of two tablet formulations of ranitidine hydrochloride in healthy volunteers.
Bawazir SA; Gouda MW; El-Sayed YM; Al-Khamis KI; Al-Yamani MJ; Niazy EM; Al-Rashood KA
Int J Clin Pharmacol Ther; 1998 May; 36(5):270-4. PubMed ID: 9629991
[TBL] [Abstract][Full Text] [Related]
34. Efficient treatment allocation in 2 × 2 multicenter trials when costs and variances are heterogeneous.
Lemme F; van Breukelen GJP; Candel MJJM
Stat Med; 2018 Jan; 37(1):12-27. PubMed ID: 28948651
[TBL] [Abstract][Full Text] [Related]
35. The role of the upper sample size limit in two-stage bioequivalence designs.
Karalis V
Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
[TBL] [Abstract][Full Text] [Related]
36. Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.
Müller HH; Pahl R; Schäfer H
Genet Epidemiol; 2007 Dec; 31(8):844-52. PubMed ID: 17549751
[TBL] [Abstract][Full Text] [Related]
37. Design and analysis issues for crossover designs in phase I clinical studies.
Boon PC; Roes KC
J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913
[TBL] [Abstract][Full Text] [Related]
38. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care.
Forbes AB; Akram M; Pilcher D; Cooper J; Bellomo R
Clin Trials; 2015 Feb; 12(1):34-44. PubMed ID: 25475880
[TBL] [Abstract][Full Text] [Related]
39. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
[TBL] [Abstract][Full Text] [Related]
40. The place of the crossover design in infertility trials: a maximum likelihood approach.
McDonnell J; Goverde AJ; Vermeiden JP
Hum Reprod; 2004 Nov; 19(11):2537-44. PubMed ID: 15459169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
